Your browser doesn't support javascript.
Benralizumab for corticosteroid-refractory DRESS in two COVID-19 patients
Swiss Medical Weekly ; 151(SUPPL 251):2S, 2021.
Article in English | EMBASE | ID: covidwho-1408023
ABSTRACT
Drug rash with eosinophilia and systemic symptoms (DRESS) is a rare severe drug hypersensitivity reaction. Treatment of DRESS currently consists of systemic corticosteroids. Here, we report benralizumab (Fasenra®) as a treatment for corticosteroid-refractory DRESS occurring in two severely ill COVID-19 patients. Both patients received high-dose intravenous corticosteroids for 4-6 days, but cutaneous symptoms, eosinophilia and signs of related organ damage were deteriorating. Based on its successful use in PDGFRA-independent hypereosinophilia, we decided to treat our patients with benralizumab. The patients showed clinical improvement and a rapid substantial drop in eosinophils. Targeted high-throughput serum proteomics prior vs. after treatment revealed a significant reduction mostly in eosinophil- and T cell response-related proteins (a.e. IL-5, CD8, TNF and PD-L1), thus pointing towards an impact of benralizumab on the (drug-directed) T cell response in DRESS.
Search on Google
Collection: Databases of international organizations Database: EMBASE Language: English Journal: Swiss Medical Weekly Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Collection: Databases of international organizations Database: EMBASE Language: English Journal: Swiss Medical Weekly Year: 2021 Document Type: Article